Search
Somatotropin
go.drugbank.com/drugs/DB00052ApprovedInvestigationalIt has an identical primary protein structure to endogenous human growth hormone.[A228188] Recombinant HGH has been commercially available since 1985 after its development by Genentech. … [Somatrem] was the first available recombinant HGH and was largely replaced by somatropin, another form of recombinant HGH.
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigational[L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS) … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.
Sennosides
go.drugbank.com/drugs/DB11365ApprovedInvestigationalThe medication is taken by mouth or via the rectum[FDA Label]. It typically begins working in minutes when given by rectum and within twelve hours when given by mouth[FDA Label]. … Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label][L771] and empty the large intestine before surgery.
Dibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalDibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse. … BMPs are subfamily of the transforming growth factor-β (TGF-β) superfamily that have different actions on the bone matrix [A31946].
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigationalThrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage. … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.
Anakinra
go.drugbank.com/drugs/DB00026ApprovedInvestigationalOn November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … [A247265] On November 8, 2022, the FDA issued an emergency use authorization (EUA) of anakinra for the treatment of COVID-19 in hospitalized patients who are at risk of progressing to severe respiratory
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigational[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity. … [L39105] It was subsequently approved by the FDA in March 2024.[L50622]
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.
Sorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigational[A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma
Synonyms: N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamideChenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalIt works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. … It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated.